全文获取类型
收费全文 | 45090篇 |
免费 | 3188篇 |
国内免费 | 1568篇 |
专业分类
耳鼻咽喉 | 522篇 |
儿科学 | 743篇 |
妇产科学 | 655篇 |
基础医学 | 12502篇 |
口腔科学 | 877篇 |
临床医学 | 3606篇 |
内科学 | 6319篇 |
皮肤病学 | 1115篇 |
神经病学 | 2298篇 |
特种医学 | 634篇 |
外国民族医学 | 13篇 |
外科学 | 3442篇 |
综合类 | 6711篇 |
现状与发展 | 5篇 |
预防医学 | 1378篇 |
眼科学 | 353篇 |
药学 | 2374篇 |
3篇 | |
中国医学 | 556篇 |
肿瘤学 | 5740篇 |
出版年
2024年 | 39篇 |
2023年 | 316篇 |
2022年 | 612篇 |
2021年 | 944篇 |
2020年 | 846篇 |
2019年 | 939篇 |
2018年 | 943篇 |
2017年 | 963篇 |
2016年 | 1111篇 |
2015年 | 1423篇 |
2014年 | 2209篇 |
2013年 | 2514篇 |
2012年 | 2493篇 |
2011年 | 3135篇 |
2010年 | 2655篇 |
2009年 | 2764篇 |
2008年 | 2765篇 |
2007年 | 2806篇 |
2006年 | 2622篇 |
2005年 | 2394篇 |
2004年 | 2122篇 |
2003年 | 1932篇 |
2002年 | 1590篇 |
2001年 | 1317篇 |
2000年 | 1273篇 |
1999年 | 1133篇 |
1998年 | 972篇 |
1997年 | 756篇 |
1996年 | 728篇 |
1995年 | 699篇 |
1994年 | 557篇 |
1993年 | 448篇 |
1992年 | 337篇 |
1991年 | 307篇 |
1990年 | 215篇 |
1989年 | 197篇 |
1988年 | 171篇 |
1987年 | 119篇 |
1986年 | 74篇 |
1985年 | 83篇 |
1984年 | 81篇 |
1983年 | 36篇 |
1982年 | 49篇 |
1981年 | 44篇 |
1980年 | 23篇 |
1979年 | 25篇 |
1978年 | 27篇 |
1977年 | 14篇 |
1975年 | 8篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Ahmed M. Abu El-Asrar Ajmal Ahmad Eef Allegaert Mohammad Mairaj Siddiquei Priscilla W. Gikandi Gert De Hertogh 《Ocular immunology and inflammation》2020,28(4):575-588
ABSTRACT
Purpose
To investigate the expression of IL-11 and its receptor IL-11Rα and to quantify density of CD163+ M2 macrophages in proliferative diabetic retinopathy (PDR). 相似文献2.
3.
背景与目的:CD44分子是众多肿瘤细胞的标志分子,其表达水平与肿瘤细胞的恶性程度有关。该研究探讨CD44基因中的单核苷酸多态性(single nucleotide polymorphism,SNP)位点与云南汉族人群宫颈癌和非小细胞肺癌(nonsmall cell lung cancer,NSCLC)易感性的相关性。方法:选取了CD44基因中的两个SNP位点rs13347和rs8193,采用TagMan基因分型的方法,分析这两个多态性位点在497例宫颈癌患者和500例健康对照个体以及483例NSCLC患者和471例健康对照个体中的分布特征,并分析CD44基因中的多态性位点与云南汉族人群宫颈癌和NSCLC的相关性。结果:rs13347和rs8193位点等位基因和基因型在宫颈癌组和对照组中的分布频率的差异无统计学意义(P>0.05)。而在NSCLC组和对照组的比较中:rs13347和rs8193位点等位基因在NSCLC组和对照组中的分布频率的差异有统计学意义(P=0.020和P=0.004);这两个位点基因型在NSCLC组和对照组中分布频率的差异有统计学意义(P=0.027和P=0.020);其中rs13347位点等位基因C在NSCLC组中的分布频率显著高于对照组,可能是NSCLC发生的风险因素(OR=1.250,95% CI:1.035~1.509),rs8193位点等位基因C在对照组中的分布频率显著高于NSCLC组,可能是NSCLC发生的保护性因素(OR=0.768,95%CI:0.641~0.921)。单倍型分析结果显示,rs13347C-rs8193T和rs13347T-rs8193C在NSCLC组和对照组中的分布频率差异有统计学意义(P=0.003和0.022);该结果说明单倍型rs13347C-rs8193T可能是云南汉族人群NSCLC发生的风险性因素(OR=1.316,95%CI:1.096~1.579)。结论:CD44基因中的两个SNP位点rs13347和rs8193可能与云南汉族人群宫颈癌发病风险无关,而可能与云南汉族人群NSCLC具有相关性。 相似文献
4.
Cis-diamminedichloridoplatinum(II)(CDDP)-based combination chemotherapy is frequently used in gastrointestinal cancer. The synergistic mechanism of all-trans retinoic acid (ATRA), cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination remains unclear. Despite their potent antitumor properties, resistance to CDDP and 5-FU develops frequently in tumors. To clarify this mechanism, we determined the sensitivity to each drug and their combination in two gastrointestinal cancer stem cells (CSCs) subpopulation.Here, we report the identification and separation of CD44+ cells from human gastric carcinoma (AGS) and human esophageal squamous cell carcinoma (KYSE-30) cancer cell lines by magnetic activated cell sorting (MACS). We allowed the CD44± cells to grow 6 days at a subtoxic concentration of ATRA and then treated with different concentration of CDDP and 5-FU for 24 h. The cytotoxicity was examined by cell proliferation MTT assay. Additionally, AO/EB staining was used for detection of apoptotic cells. In order to determine whether the growth inhibition was also associated with changes in cell cycle distribution, cell cycle analysis was performed using flow cytometry.Low concentration of ATRA (1 μM, 6days) followed by 5-FU and CDDP was found to be more effective than either drugs alone, thus resulting in synergistic cytotoxicity in Kyse-30 and AGSCD44± cells. Furthermore, there was an indication that the combination of ATRA with 5FU and CDDP caused an increase in cell cycle arrest in G2/M and G0/G1.We conclude that low concentration of ATRA enhances the cytotoxicity of CDDP and 5FU by facilitating apoptosis and cell cycle arrest in gastrointestinal CSCs and provide a rational basis for the design of novel, well-tolerated CDDP- and 5FU-based chemotherapy in human gastrointestinal carcinoma. 相似文献
5.
目的比较骨填充网袋椎体成形术(Vesselplasty)与经皮椎体后凸成形术(percutaneous kyphoplasty,PKP)治疗 Kümmell 病的临床疗效。方法2015 年 1 月—2018 年 12 月收治 63 例 Kümmell 病患者,其中 28 例采用 Vesselplasty 治疗(Vesselplasty 组),35 例采用 PKP 治疗(PKP 组)。两组患者性别、年龄、病程、骨密度 T 值、骨折节段及术前疼痛视觉模拟评分(VAS)、Oswestry 功能障碍指数(ODI)、伤椎前缘高度、后凸 Cobb 角等一般资料比较,差异均无统计学意义(P>0.05),具有可比性。记录两组手术时间、术中透视时间、骨水泥注射量、骨水泥渗漏率、骨水泥弥散面积率和随访期间并发症发生情况,以及术前、术后 1 d、末次随访时 VAS 评分、ODI、伤椎前缘高度、后凸 Cobb 角。 结果两组患者均获随访,随访时间 12~36 个月,平均 24.2 个月。Vesselplasty 组手术时间、术中透视时间、骨水泥注射量、骨水泥弥散面积率均明显小于 PKP 组(P<0.05)。Vesselplasty 组骨水泥渗漏率(7.14%)明显低于 PKP 组(34.29%)(χ2=5.153,P=0.023)。两组患者术后 1 d 及末次随访时 VAS 评分、ODI、伤椎前缘高度、后凸 Cobb 角均较术前显著改善(P<0.05),术后两组间比较差异均无统计学意义(P>0.05)。随访期间两组均未见术椎再塌陷,Vesselplasty 组邻椎骨折发生率(7.14%)与 PKP 组(14.29%)比较,差异无统计学意义(χ2=0.243,P=0.622)。 结论Vesselplasty 和 PKP 治疗 Kümmell 病疗效相似,均能有效缓解患者疼痛症状,改善生活质量,部分恢复伤椎高度,矫正椎体后凸。但前者具有手术时间短、术中透视时间少、骨水泥渗漏少等优势。 相似文献
6.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
7.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
8.
Haonan Guo Rui Zhang Justice Afrifa Yuanyuan Wang Jingcui Yu 《Pathology, research and practice》2019,215(6):152403
PurposeWe previously demonstrated that the functional inactivation of DAL-1 and TOB1 promotes an aggressive phenotype in gastric cancer cells, but the links between both genes and the survival of patients with gastric cancer are unknown. Here, we investigated the correlations of the expression levels of DAL-1 and TOB1 with the progression of gastric cancer.MethodsA total of 270 patients who underwent resectable gastrectomy were included. The expression of DAL-1 and TOB1 was detected by immunohistochemistry.ResultsLow expression of DAL-1 in cancer tissue was significantly associated with tumor site (p < 0.05), histological grade (p < 0.01), depth of invasion (p < 0.05), lymph node metastasis status (p < 0.05), Lauren classification (p < 0.001), and clinical stage (p < 0.01). A lower level of TOB1 was observed in gastric cancer patients with diffuse type disease compared to patients with either intestinal or mixed type disease (p < 0.001). Additionally, Spearman’s correlation analysis revealed that decreased expression of DAL-1 was positively correlated with low TOB1 expression (r=0.304, p < 0.001). The survival analysis showed that low levels of DAL-1 and TOB1 were significantly associated with poor survival of gastric cancer patients (p <0.001 and p < 0.05, respectively).ConclusionThe downregulation of DAL-1 and TOB1 expression is associated with shorter survival of gastric cancer patients. Hence, DAL-1 and TOB1 may be considered potential novel markers for predicting the outcomes of patients with gastric cancer. 相似文献
9.
《Immunity》2022,55(7):1316-1326.e4
- Download : Download high-res image (134KB)
- Download : Download full-size image
10.
《Journal of thoracic oncology》2019,14(10):1818-1827
IntroductionProgrammed death ligand 1 (PD-L1) expression is a predictive biomarker for patient response to nivolumab in nonsquamous NSCLC. However, the number of biopsy samples and tumor cells (TCs) required to assess PD-L1 expression remains unclear.MethodsA total of 222 biopsy samples from 80 patients with nonsquamous NSCLC treated with nivolumab were collected. Number of TCs and PD-L1 score were compared among the sample containing the largest number of TCs (Max-TC), the sample containing the smallest number of TCs (Min-TC), and the total samples from each patient. The impact of the number of samples and TCs on the prediction of patient response to nivolumab with use of PD-L1 scores was evaluated.ResultsThere was a mismatch in PD-L1 scores less than 1% and those of at least 1% between Max-TC and the total samples in one patient (1%) and between Max-TC and Min-TC in six patients (8%). The optimal number of TCs to match PD-L1 expression less than 1% versus at least 1% between Max-TC and Min-TC was 100 (sensitivity = 0.676 and 1 – specificity = 0.333). PD-L1 expression of at least 1% in Min-TCs containing at least 100 TCs was associated with longer progression-free survival (median 7.6 versus 1.8 months [p < 0.01]) and overall survival (median not reached versus 9.9 months [p = 0.04]) compared with PD-L1 expression less than 1%. However, there were no differences in progression-free survival (median 3.9 versus 2.3 months [p = 0.37]) or overall survival (median 9.7 versus 7.6 months [p = 0.60]) between PD-L1 expression of at least 1% and PD-L1expression less than 1% in Min-TCs containing fewer than 100 TCs.ConclusionSingle biopsy samples containing at least 100 TCs are required to evaluate PD-L1 expression for predicting patient response to nivolumab. 相似文献